title: Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
authors.affiliation: University of Barcelona, Barcelona, Spain.
authors.forename: Jose M
authors.initials: JM
authors.lastname: Gatell
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
authors.forename: Beatriz
authors.initials: B
authors.lastname: Grinsztejn
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Eron
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Daniel
authors.initials: D
authors.lastname: Vittecoq
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Gonzalez
authors.forename: Robert M
authors.initials: RM
authors.lastname: Danovich
authors.forename: Hong
authors.initials: H
authors.lastname: Wan
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Anne R
authors.initials: AR
authors.lastname: Meibohm
authors.forename: Kim M
authors.initials: KM
authors.lastname: Strohmaier
authors.forename: Charlotte M
authors.initials: CM
authors.lastname: Harvey
authors.forename: Robin D
authors.initials: RD
authors.lastname: Isaacs
authors.forename: Bach-Yen T
authors.initials: BY
authors.lastname: Nguyen
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium